by Annie De Groot | Oct 2, 2018 | News, Thinking Out Loud -Blog
Revolutionizing Risk Assessment: Generic Peptide Drugs and Their Impurities EpiVax has been awarded a $1 million contract from the Food and Drug Administration (FDA) to demonstrate and validate the best practices and procedures for assessing generic peptide drugs and...
by Annie De Groot | May 24, 2018 | Thinking Out Loud -Blog
Hello, protein therapeutics developers! We’re presenting some work in Montpellier at the Antibody Industrial Symposium (AIS) and we thought we’d share in advance of the presentation. Why? Because we thought you would want to know that Tregitope content is...
by Annie De Groot | Nov 16, 2017 | Thinking Out Loud -Blog
When Tofu isn’t Turkey . . . We’re in Lisbon at the European Immunogenicity Platform meeting (EIP -OK, somebody has to do it!). Alex Sette just finished his talk about the new IEDB tool for de-immunization. We’re thrilled to hear that he’s...
by Annie De Groot | Oct 26, 2017 | EpiVax Immunoncology, Thinking Out Loud -Blog
Yes, wonder drugs though they are, checkpoint inhibitors (a.k.a CPI) drive anti-drug antibodies (ADA) too. We’ve been concerned for a while that “releasing the brakes” will drive T cell response to CPI, and have been watching to see what happens....
by Admin Epivax | Aug 30, 2017 | Events
It’s a Dutch Treat! The 3rd Annual Immunogenicity and Tolerance Seminar November 9th, 2017 [Updated] View Event Photos!...
